
Pharmacy Leaders Map Path for Outpatient Bispecifics, CAR T
Pharmacy leaders from academic and community practices discuss the infrastructure, partnerships, and payer strategies for outpatient access.
Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies are moving toward earlier lines of treatment and, eventually, beyond oncology.1,2 For pharmacy leaders, the question is no longer whether these therapies will reach the outpatient setting but how to get them there safely and sustainably. A panel at the 2026 Patient-Centered Oncology Care® conference explored what that shift demands operationally, financially, and collaboratively.
Moderator Andre Harvin, PharmD, MS, MBA, BCPS, chief pharmacy officer at the University of Maryland Medical System, framed the discussion from personal experience. Less than 2 years ago, he led pharmacy at a community-based health system weighing whether to offer CAR T. Now, at an academic medical center, he is asking the reverse: how to get patients out of the hospital and closer to home.
From Academic Centers Into Community Practices
For complex therapies, the journey usually begins at an academic center. LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, director of pharmacy and clinical oncology at Atrium Health, said that is where teams first learn to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome, then pass that knowledge to community practices. Step-up dosing often stays at the academic site until toxicities become less common.
Bispecifics make that handoff relatively easy because they are “a pharmacy kind of owned product,” Kennedy said. CAR T is another matter. Apheresis, receipt and storage of cellular products, and other infrastructure can be difficult for smaller practices to build.
Sam Abdelghany, PharmD, MHA, BCOP, executive director of pharmacy at Yale Smilow Cancer Hospital, challenged the framing of academic vs community altogether. His health system spans both, and in practice, that has produced several models. Some patients receive every dose and cycle in a single setting. Others begin with step-up doses at one location before graduating to another site or sharing care between them. Moving into earlier lines of therapy may even simplify matters, he suggested, because patients are less pretreated and less frail.
“You just need to have that structure put in place to manage the patients, regardless of where they want to be,” he said.
For Florida Cancer Specialists & Research Institute, which operates nearly 100 sites, the strategy has shifted over time. Kristen Boykin, PharmD, BCOP, BCPS, director of pharmacy operations, said the organization initially targeted care disparities, looking for areas where patients could not travel to an academic center for an entire course of treatment but could make the trip for the first month. Now the question is capacity. As therapies move earlier, a single site in a region may no longer be enough, and locations once considered adequately served by a nearby center may need to offer these treatments themselves.
The patient benefit is straightforward, said Joey Hollenbeck, PharmD, senior director of pharmacy services at OneOncology. Treatment close to home spares patients hours of driving and city traffic while they are coping with the hardships of their disease.
Pharmacy’s Expanding Role
Pharmacy’s contribution goes well beyond Risk Evaluation and Mitigation Strategies compliance and drug procurement. Abdelghany described pharmacy involvement at nearly every step, from contracting to electronic health record builds that embed the criteria needed to treat patients safely, whether in the inpatient or fully outpatient setting. His team also created an emergency department (ED) care pathway. When a patient on one of these therapies arrives, an alert flags a possible case of CRS and links to management guidelines. With ED staff constantly rotating, systems cannot rely on particular people having been trained.
Pharmacists have also driven clinical progress. As an example, Kennedy pointed to prophylactic use of tocilizumab, which was once dismissed. Pharmacists worked through questions of dose and setting, generating data that have since been published and presented.3-5
Education is another front. Hollenbeck said pharmacists can broker relationships between community practices and hospitals and engage manufacturers to train staff in both the practice and the ED. The stakes are significant, he said, because CRS “can present as a lot of other things and get treated completely the wrong way” if clinicians do not know a patient is on one of these therapies.
Boykin attributed the breadth of pharmacy’s role to habit and training. Pharmacists are used to figuring things out beyond what they learned in school, she said, and they tend to see the entire patient journey “from A to Z.” That perspective also tells them when to hand work to others: “99.9% of my job, I’m pulling in another discipline to help,” she said.
No Need to Reinvent the Wheel
Panelists agreed that new programs should borrow liberally. Kennedy encouraged academic centers to share checklists and lessons from onboarding these products, noting that some manufacturers offer their own. Abdelghany’s team provided order sets and CRS management guidelines to an unaffiliated community practice about 20 minutes from his hospital. “Somebody’s done it—use it, customize it, but no need to really start from the beginning,” he said.
Hollenbeck described how that philosophy works at the network level. OneOncology has developed checklists for partner practices and urges even those only considering these therapies to start preparing rather than scrambling when a candidate appears. If a practice is not ready, an academic center can start the patient on therapy and transition care back afterward.
Expansion brings its own education burden, Kennedy added. Bispecifics for myeloma differ from those for lymphoma, and teams treating solid tumors, along with the generalists in community practices, must learn different terminology and toxicity profiles. “It isn’t one size fits all,” she said.
Abdelghany offered a note of caution. Starting a program carries financial and operational risk, and a nearby center that can do more may be the better option. “Just because you can, that doesn’t mean you should,” he said.
For those practices that decide to proceed, Boykin said, the next step is to identify how they differ from existing programs and which resources they lack. Florida Cancer Specialists & Research Institute is not a hospital and has no apheresis center, so it contracts with outside entities. “If you’ve answered the question that you should do this, then you will find a way,” she said.
Payers and Financial Pressures
Cost of care came up repeatedly. Outpatient delivery is generally less expensive, Kennedy said, but the quality must hold. She advocated negotiating around the total cost of care rather than per diem rates or drug costs alone, and considering short observation stays instead of full admissions.
Abdelghany called access the most pressing problem. Yale added a sickle cell gene therapy to its formulary almost 2 years ago and has yet to treat a patient. He argued for outcome-based payment for these costly therapies: “You should pay for something that works.”
Payer education remains a heavy lift. Boykin said Florida payers are where they were with bispecifics a few years ago, which requires patience as her team explains the value of community delivery. Hollenbeck noted that payers often lump CAR T in with transplant, so practices that are not certified centers frequently need single-case agreements. Bispecifics, by contrast, are recognized differently.
Advice for Programs Just Starting
When asked what newcomers should do first, panelists were clear: Ask for help. Published standard operating procedures have made the on-ramp “less steep,” Boykin said, and successful programs are generally glad to share. She also urged practices to tap manufacturer education sessions and patient kits that include blood pressure monitors, pulse oximeters, and thermometers.
Hollenbeck’s former practice visited established programs to watch how they worked, and OneOncology now pairs practices learning to use bispecifics with those that have some experience. Programs need not be high-tech, Abdelghany said. His team sends patients home with a thermometer, whereas others use remote monitoring and bots.
Kennedy closed with a dose of realism. “Yes, we've shortened the on-ramp, but we're not quite there that we can just do this quickly.” Having realistic expectations, assembling the right team, and careful preparation will allow expansion in cellular therapies beyond hematological cancers into solid tumors.
References
- Anderson LD Jr, Dhakal B, Jain T, et al. Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30(1):17-37. doi:10.1016/j.jtct.2023.10.022
- Schett G, Müller F, Taubmann J, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531-544. doi:10.1038/s41584-024-01139-z
- Kowalski A, Lykon J, Diamond B, et al. Emerging strategies for the prevention of immune toxicities associated with T cell-engaging cancer therapies. Blood Cancer Discov. 2024;5(2):90-94. doi:10.1158/2643-3230.BCD-23-0228
- Kowalski A, Lykon J, et al. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. Blood. 2024;144(suppl 1):932. doi:10.1182/blood-2024-203426
- Scott SA, Marin EM, Maples KT, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer J. 2023;13(1):191. doi:10.1038/s41408-023-00963-y
Related to this article




